Effects of the RGD loop and C-terminus of rhodostomin on regulating integrin αIIbβ3 recognition

Yao-Tsung Chang¹, Jia-Hau Shiu¹, Chun-Hao Huang¹, Yi-Chun Chen¹, Yung-Sheng Chang², Woei-Jer Chuang¹,²* 

¹Institute of Basic Medical Sciences and Department of Biochemistry and Molecular Biology, Tainan, Taiwan, ²Institute of Biopharmaceutical Sciences, National Cheng Kung University College of Medicine, Tainan, Taiwan
* Current address: Department of Biochemistry and Molecular Biology, National Cheng Kung University College of Medicine, Tainan, Taiwan

WJCNMR@mail.ncku.edu.tw

Abstract

Rhodostomin (Rho) is a medium disintegrin containing a 48PRGDMP motif. We here showed that Rho proteins with P48A, M52W, and P53N mutations can selectively inhibit integrin αIIbβ3. To study the roles of the RGD loop and C-terminal region in disintegrins, we expressed Rho 48PRGDMP and 48ARGDWN mutants in Pichia pastoris containing 65P, 65PR, 65PRYH, 65PRNGLYG, and 65PRNPWNG C-terminal sequences. The effect of C-terminal region on their integrin binding affinities was αIIbβ3 > αvβ3 > α5β1, and the 48ARGDWN-65PRNPWNG protein was the most selective integrin αIIbβ3 mutant. The 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants had similar activities in inhibiting platelet aggregation and the binding of fibrinogen to platelet. In contrast, 48ARGDWN-65PRYH and 48ARGDWN-65PRNGLYG exhibited 2.9- and 3.0-fold decreases in inhibiting cell adhesion in comparison with that of 48ARGDWN-65PRNPWNG. Based on the results of cell adhesion, platelet aggregation and the binding of fibrinogen to platelet inhibited by ARGDWN mutants, integrin αIIbβ3 bound differently to immobilized and soluble fibrinogen. NMR structural analyses of 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants demonstrated that their C-terminal regions interacted with the RGD loop. In particular, the W52 sidechain of 48ARGDWN interacted with H68 of 65PRYH, L69 of 65PRNGLYG, and N70 of 65PRNPWNG, respectively. The docking of the 48ARGDWN-65PRNPWNG mutant into integrin αIIbβ3 showed that the N70 residue formed hydrogen bonds with the αβ3 D159 residue, and the W69 residue formed cation-π interaction with the β3 K125 residue. These results provide the first structural evidence that the interactions between the RGD loop and C-terminus of medium disintegrins depend on their amino acid sequences, resulting in their functional differences in the binding and selectivity of integrins.
Introduction

RGD-containing disintegrins are potent integrin inhibitors that were found in snake venoms [1–4]. They are classified into small, medium, long, and dimeric disintegrins based on their size and the number of disulfide bonds [5]. Short disintegrins are composed of 41 to 51 residues and four disulfide bonds; medium disintegrins contain approximately 70 amino acids and six disulfide bonds; long disintegrins include a polypeptide with approximately 84 residues cross-linked by seven disulfide bonds; and homo- and hetero-dimeric disintegrins contain each subunit of approximately 67 residues with a total of ten disulfide bonds involved in the formation of four intrachain disulfides and two interchain disulfides [6]. A common structural feature of RGD-containing disintegrins is the presence of a solvent-exposed RGD tripeptide, which is crucial to the recognition of integrins [7]. The pairing of cysteine residues in disintegrins play an important role in exposing the RGD binding motif that mediates inhibition of platelet aggregation, neutrophil or endothelial cell function [1–7]. Disintegrins are therefore used to develop anti-platelets agents and anti-angiogenesis inhibitors for cancer [1–6].

Many studies have shown that the residues flanking the RGD motif and in the C-terminal region of disintegrins affect their integrins binding specificities and affinities [8–15]. For example, disintegrins with an ARGD sequence exhibit a higher affinity for binding with integrin αIIbβ3, whereas disintegrins with an ARGDN sequence preferentially bind with integrins αvβ3 and α5β1 [10]. The amino acid sequences of RGD loop of rhodostomin (Rho) was mutated from RIPRGDMP to TAVRGDGP, resulting in a 196-fold decrease in the inhibition of integrin αIIbβ3 [12]. Replacing the N-terminal alanine with the proline of the RGD motif of elagantin (a disintegrin with an ARGDMP sequence) diminishes its ability to bind to integrin α5β1 [13]. The N-terminal proline residue adjacent to the RGD motif of Rho affects its function and dynamics [14]. Deletion and mutagenesis studies on echistatin have demonstrated that its C-terminal tail is important for its activity in inhibiting platelet aggregation [11, 15].

Many functional studies showed that the C-terminal tails of disintegrins act with the RGD loop to regulate integrins recognition [8, 11, 16–22]. For example, Marcinkiewicz et al. reported that the C-terminal region of echistatin supports integrin binding and plays a crucial role in the expression of ligand-induced binding site (LIBS) epitope and in the conformational changes of the integrins [11]. The C-terminal tail of RWN residues of trimestatin are positioned close to the C-terminal side of the RGD loop and act as a secondary determinant of integrin-binding potency [18]. In particular, eristostatin requires an ARGW motif and an intact C-terminus (NPWNG) to interact with both platelets and melanoma cells [19]. Eristostatin and bitistatin contain an ARGDWM motif with different C-terminal tails, and eristostatin exhibits a higher affinity to resting platelets [20, 23]. However, the structural basis and mechanism underlying how integrins are recognized by the C-terminus and RGD loop of disintegrins are unclear.

To examine how the C-terminus interacts with the RGD loop to recognize integrin αIIbβ3, we analyzed disintegrins containing an ARGDWM loop and found that they mainly exhibited C-termini with NGLYG and NPWNG amino acid sequences (Fig 1). Therefore, we used Rho as the model protein to study the effects of the ARGDWM/PRGDMP loops and C-terminal regions on the structure-activity relationships of disintegrin. Rho is obtained from Calloselasma rhodostoma venom and belongs to the disintegrin family [24]. It consists of 68 amino acids, including 12 residues of cysteine and a PRGDMP sequence at positions 48 to 53. We have demonstrated that Rho expressed in Pichia pastoris has the same function and structure as the native protein [25, 26]. In this study, we expressed Rho containing an ARGWWM or PRGDMP loop with different C-terminal sequences in P. pastoris, determined their activity in the inhibition of integrins, and used nuclear magnetic resonance (NMR) spectroscopy to
compare their structural differences. We also docked these mutants into integrin αIIbβ3 and analyzed their interactions. The results demonstrated that the RGD loop and C-terminus of medium disintegrins interact with each other, resulting in structural and functional differences relevant to integrin binding.

Materials and methods

Expression of Rho mutants in *P. pastoris* and purification

The expression of Rho mutants, including 48PRGDMP.65PR, 48PRGDMP.65PRNGLYG, 48PRGDMP.65PRNPWNG, 48ARGDWN.65P, 48ARGDWN.65PR, 48ARGDWN.65PPRY, 48ARGDWN.65PPRYH, 48ARGDWN.65PRNGLYG, and 48ARGDWN.65PRNPWNG, in *P. pastoris* and purification were accomplished by following previously described protocols [26–28].

Mass spectrometric measurements

The molecular weights of proteins were confirmed using an LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source (Thermo Fisher Scientific). The protein solutions (1–10 μM in 50% methanol with 0.1% formic acid) were infused into the mass spectrometer by using a syringe pump at a flow rate of 3 μL/min to acquire full scan mass spectra. The electrospray voltage at the spraying needle was optimized at 4000 V. The molecular weights of proteins were calculated by computer software Xcalibur that was provided by the Thermo Fisher Scientific.

Cell adhesion assay

The adhesions of CHO-αIIbβ3 cells to fibrinogen, CHO-αvβ3 cells to fibrinogen, and K562 cells to fibronectin were used to determine the inhibitory activities of Rho mutants to integrins αIIbβ3, αvβ3, and α5β1. They were conducted according to previously described protocols [14, 27].
Preparation of human platelets

Platelets were collected using 0.15 vol/vol acid-citrate dextrose (ACD) containing 85 mM trisodium citrate, 2% dextrose and 65 mM citric acid as the anticoagulant and washed using a modification of a previously described method [29]. 12 mL of blood was centrifuged at 150 x g for 10 min at room temperature (RT). The buffy coat and the red blood layers were discarded to avoid the contaminants. The remaining 5 ml of platelet-rich plasma (PRP) layer was acidified to pH 6.5 with 5 ml of ACD and then added 1 μL of 10 mM prostaglandin E1 (PGE1). Platelets were pelleted by centrifugation at 750 g for 10 min at room temperature (RT), and the supernatant was removed. The platelet pellet was gently re-suspended in 5 mL of 130 mM NaCl, 3 mM KCl, 10 mM trisodium citrate, 9 mM NaHCO₃, 6 mM dextrose, 0.9 mM MgCl₂, 0.81 mM KH₂PO₄, and 10 mM Tris (JNL) buffer at pH 7.4. Platelets were counted using a XT-1800-Hematology-Analyzer and were adjusted to 1×10⁸ per ml. Platelets were allowed to stand at RT for 45 min to let PGE1 dissipate. 20 μL of 18 mM calcium chloride was immediately added into 2 mL of platelet solution before the fibrinogen binding experiment.

Fibrinogen binding assay

The fibrinogen (Fg) binding assay was accomplished using a modification of a previously described method [29]. Rho and its mutants (40–2000 nM), which were used as inhibitors, were added to 5 μL of 2.5 mg/mL Oregon Green 488-labeled fibrinogen (Invitrogen, UK). 20 μL aliquots of washed platelet suspension were then added and incubated for 30 min before the addition of 10 μM ADP. The resulting platelet solutions were incubated at RT for a further 30 min. The reaction was stopped by addition of 1 mL ice-cold buffer. The binding of Fg to platelets was detected using a flow cytometry. Data acquisition and analysis were performed with the Cell Quest program. Platelet populations were gated for the analysis, and the histograms of mean fluorescence were generated for each sample. Statistical analysis was performed on the geometric scale. All experiments were run in duplicate, and the reported IC₅₀ values are the average of at least three separate experiments.

Platelet aggregation assay

The inhibition of platelet aggregation by Rho mutants was accomplished by following previously described protocols [14, 27].

Structure determination by nuclear magnetic resonance spectroscopy

Structure determination of Rho ⁴⁸ARGDWN⁻⁶⁵PRYH, ⁴⁸ARGDWN⁻⁶⁵PRNGLYG, and ⁴⁸ARGDWN⁻⁶⁵PRNPWNG mutants by NMR spectroscopy was described in detail previously [30–32]. NMR experiments were performed at 27˚C on a Bruker Avance 600 spectrometer equipped with pulse field gradients and xyz-gradient triple-resonance probes. Structures were calculated using the X-PLOR program and the hybrid distance geometry-dynamical simulated annealing method [30, 31]. The structure figures were prepared using the MOLMOL [32] and PyMOL (http://www.pymol.org) programs.

Molecular docking

The docking of Rho mutants to integrin αIIbβ3 was performed on the HADDOCK webserver by using hydrogen bond and distance restraints as described previously [33]. The starting structures for the docking were NMR structures of Rho mutants and integrin αIIbβ3 (PDB code 3ZE2) [34]. The interaction restraints were derived from the X-ray structure of integrin αIIbβ3 in complex with a GRGDSP peptide by using CCP4i software (http://structure.usc.edu/ccp4/).
The selected structure cluster for the analysis was based on the lowest Z-score without any restraint violations. Hydrogen bonds and salt bridges were analyzed using PISA software (http://www.ebi.ac.uk/msd-srv/prot_int/). Cation-π interactions and non-bonded contacts were determined using CaPTURE (http://capture.caltech.edu/) and CCP4i, respectively [35].

Protein data bank accession number and nuclear magnetic resonance assignment
The coordinates of 20 calculated structures of Rho \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH, \textsuperscript{48}ARGDWN\textsuperscript{−65}PRNGLYG, and \textsuperscript{48}ARGDWN\textsuperscript{−65}PRNPWNG mutants were deposited in the Protein Data Bank under accession numbers 2M75, 2M7F, and 2M7H, respectively. \textsuperscript{1}H and \textsuperscript{15}N resonances of Rho \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH, \textsuperscript{48}ARGDWN\textsuperscript{−65}PRNGLYG, and \textsuperscript{48}ARGDWN\textsuperscript{−65}PRNPWNG mutants were deposited in the BioMagResBank databank under accession numbers 19210, 19211, and 19212, respectively.

Results
Protein expression and purification of rhodostomin mutants
Rho mutants were expressed in \textit{P. pastoris} X33 strain by using the pPICZ\textalpha{}A vector. Recombinant Rho mutants proteins were purified to homogeneity by Ni\textsuperscript{2+}-chelating chromatography and C18 reversed-phase HPLC. According to SDS-polyacrylamide gel electrophoresis analysis (data not shown), the purified Rho mutants proteins were homogenous. The final yields of unlabelled Rho mutants produced in \textit{P. pastoris} were 10 to 25 mg/L, and the final yields of \textsuperscript{15}N-labeled Rho mutants were 5 to 15 mg/L.

Mass spectrometry was used to determine the molecular weights of recombinant Rho mutants. Mass spectrometry indicated that the experimental molecular weights deviated less than 1 Da from the theoretical values, which were calculated by assuming that all cysteines formed disulfide bonds in Rho mutants. For example, the experimental molecular weight of Rho \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH mutant was 8464.0 Da, which was in excellent agreement with the calculated value of 8463.4 Da (Figure A in S1 File). The molecular weight of the recombinant Rho mutant had an additional 1117.2 Da from the eight extra amino acid residues (EFHHHHHHH) at the N-terminus. The mass of 8463.4 Da was calculated by assuming that all cysteines formed disulfide bonds, indicating that six disulfide bonds formed in the \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH mutant. The results indicated the formation of six disulfide bonds in all Rho mutants (Figure A and Table A in S1 File).

Inhibition of integrins αIIbβ3, αvβ3, and α5β1
Inhibition of cell-expressing integrins αIIbβ3, αvβ3, and α5β1 to their ligands by Rho mutants was used to determine their activity and selectivity (Tables 1, 2 and 3). Rho and its \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH mutant inhibited the adhesion of CHO cells that expressed integrin αIIbβ3 to immobilized fibrinogen with IC\textsubscript{50} values of 52.2 \pm 8.2 and 162.8 \pm 7.2 nM, respectively (Table 1). In contrast, Rho and its \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH mutant inhibited the adhesion of CHO cells that expressed integrin αvβ3 to immobilized fibrinogen with IC\textsubscript{50} values of 13.0 \pm 5.7 and 246.6 \pm 66.8 nM, respectively. Rho and its \textsuperscript{48}ARGDWN\textsuperscript{−65}PRYH mutant inhibited integrin α5β1 adhesion to immobilized fibronectin with IC\textsubscript{50} values of 256.8 \pm 87.5 and 8732.2 \pm 481.8 nM, respectively. Their differences in inhibiting integrins αIIbβ3, αvβ3, and α5β1 were 3.1-, 19.0-, and 34.0-fold. These results indicated that Rho containing a \textsuperscript{48}ARGDWN sequence exhibited selectivity for binding with integrin αIIbβ3.
We expressed a series of Rho C-terminal mutants to confirm their effects on inhibiting integrins (Table 2). Rho \(48\) ARGDWN, \(65\)P, \(65\)PR, \(65\)PRY, \(65\)PRYH, \(65\)PRNGLYG, and \(65\)PRNPWNG mutants inhibited the adhesion of CHO cells that expressed integrin \(\alpha I\beta3\) to immobilized fibrinogen with \(IC_{50}\) values of 1314.0, 723.0, 104.2, 162.8, 170.6, and 57.0 nM, respectively. The \(48\)ARGDWN, \(65\)PR mutant was 6.9-fold less active than the \(48\)ARGDWN-\(65\)PRY mutant, suggesting that the Y67 residue may play important role in inhibiting the adhesion of integrin \(\alpha I\beta3\) to immobilized fibrinogen. These Rho mutants inhibited the adhesion of CHO cells that expressed integrin \(\alpha I\beta3\) to immobilized fibrinogen with \(IC_{50}\) values of 868.9, 467.3, 222.5, 246.6, 1191.8, and 1207.0 nM, respectively. They inhibited K562 cell adhesion to immobilized fibronectin with \(IC_{50}\) values of 7616.3, 3397.0, 8938.0, 8732.3, 9529.3, and 2548.6 nM, respectively. The affinity differences in inhibiting integrins \(\alpha I\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) were ranged from 1.0 to 23.1-, 0.2 to 1.0-, and 1.0 to 3.7-folds. These results demonstrated that the effect of C-terminal regions on the change of their relative binding affinity to integrins was \(\alpha I\beta3 > \alpha V\beta3 > \alpha V\beta1\). The \(48\) ARGDWN-\(65\)PRNPWNG protein was the most selective integrin \(\alpha I\beta3\) mutant and inhibited integrins \(\alpha I\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) with \(IC_{50}\) values of 57.0, 1207.0, and 2548.6 nM, respectively.

We also expressed Rho mutants containing a \(48\)PRGDMP sequence with different C-terminal tails, including \(48\)PRGDMP-\(65\)P, \(48\)PRGDMP-\(65\)PR, \(48\)PRGDMP-\(65\)PRY, \(48\)PRGDMP-\(65\)PRNGLYG, and \(48\)PRGDMP-\(65\)PRNPWNG mutants, to examine the roles of the C-terminal regions (Table 3). Their affinity differences in inhibiting integrins \(\alpha I\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) were ranged from 1.0 to 11.4-, 1.0 to 1.8-, and 0.9 to 2.3-folds. These results indicated that the effects of C-terminal regions on the change of their relative binding affinity to integrins was \(\alpha I\beta3 > \alpha V\beta3 > \alpha V\beta1\). In contrast, the \(48\)PRGDMP-\(65\)PRNPWNG mutant did not exhibit any integrin selectivity and inhibited integrins \(\alpha I\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) with \(IC_{50}\) values of 235.2, 40.7, and 260 nM, respectively. These findings revealed that the \(48\) ARGDWN sequence selectively inhibited

---

Table 1. Inhibition of integrins \(\alpha II\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) by Rho and its \(48\)ARGDWN mutants.

| Proteins | \(\alpha II\beta3 / Fg\) | \(\alpha V\beta3 / Fg\) | \(\alpha V\beta1 / Fn\) |
|---|---|---|---|
| RGD Loop | C-terminus | \(IC_{50}\) (nM) | \(Q\) | \(IC_{50}\) (nM) | \(Q\) | \(IC_{50}\) (nM) | \(Q\) |
| \(48\)PRGDMP | \(65\)PRYH | 52.2±8.2 | 1.0 | 13.0±5.7 | 1.0 | 256.8±87.5 | 1.0 |
| \(48\)ARGDWN | \(65\)PRYH | 162.8±10.9 | 3.1 | 246.6±66.8 | 19.0 | 8732.3±481.8 | 34.0 |
| Folds | | 3.1 | | 19.0 | | 34.0 | |

\(Q\) ratio = \(IC_{50} [\text{Rho or its mutants}] / IC_{50} [\text{Rho}]\)

https://doi.org/10.1371/journal.pone.0175321.t001

Table 2. Inhibition of platelet aggregation integrins \(\alpha II\beta3\), \(\alpha V\beta3\), and \(\alpha V\beta1\) by Rho \(48\)ARGDWN mutants.

| Proteins | \(\alpha II\beta3 / Fg\) | \(\alpha V\beta3 / Fg\) | \(\alpha V\beta1 / Fn\) |
|---|---|---|---|
| RGD Loop | C-terminus | \(IC_{50}\) (nM) | \(Q\) | \(IC_{50}\) (nM) | \(Q\) | \(IC_{50}\) (nM) | \(Q\) |
| \(48\)ARGDWN | \(65\)PRNPWNG | 57.0±12.5 | 1.0 | 1207.0±73.5 | 1.0 | 2548.6±313.8 | 1.0 |
| \(48\)ARGDWN | \(65\)P | 1314.0±121.5 | 23.1 | 868.9±87.5 | 0.7 | 7616.3±913.9 | 3.0 |
| \(48\)ARGDWN | \(65\)PR | 723.0±163.7 | 12.7 | 467.3±113.4 | 0.4 | 3397.0±426.1 | 1.3 |
| \(48\)ARGDWN | \(65\)PRY | 104.2±10.1 | 1.8 | 222.5±10.7 | 0.2 | 8938.0±1099.3 | 3.5 |
| \(48\)ARGDWN | \(65\)PRYH | 162.8±10.9 | 2.9 | 246.6±66.8 | 0.2 | 8732.3±481.8 | 3.4 |
| \(48\)ARGDWN | \(65\)PRNGLYG | 170.6±24.7 | 3.0 | 1191.8±378.7 | 1.0 | 9529.3±1224.8 | 3.7 |
| Folds | | 1.0–23.1 | 0.2–1.0 | 1.0–3.7 |

\(Q\) ratio = \(IC_{50} [\text{Rho 48 ARGDWN mutants}] / IC_{50} [\text{Rho 48 ARGDWN-65PRNPWNG mutant}]\)

https://doi.org/10.1371/journal.pone.0175321.t002
integrin αIIbβ3. We also found that the incorporation of C-terminal NPWNG sequence with ARGDWN loop increased the inhibitory activity against integrin αIIbβ3.

### Inhibition of platelet aggregation

Recombinant Rho inhibited platelet aggregation with a Kᵢ of 83.2 ± 10.4 nM, and the mutation of P48A, M52W, and P53N (48ARGDWN-65PRYH mutant) on Rho caused a 1.5-fold decrease in activity in the inhibition of platelet aggregation with a Kᵢ of 128.0 ± 14.2 nM (Table 4). To study the effects of the C-terminus on the inhibition of platelet aggregation, we expressed 48ARGDWN-65PRNGLYG and 48ARGDWN-65PRNPWNG mutants. The average IC₅₀ values of 48ARGDWN-65PRNGLYG and 48ARGDWN-65PRNPWNG mutants were 105.2 and 107.9 nM, respectively, which were similar to the average IC₅₀ values of wild-type Rho [24]. In contrast, the average IC₅₀ values of 48ARGDWN-65PR and 48ARGDWN-65PRY mutants were 235.1 and 171.4 nM, suggesting the importance of the R66 residue (Table 4). These results showed that the length of the C-terminus and the R66 residue of Rho with an 48ARGDWN loop sequence are essential for interacting with platelets integrin αIIbβ3.

We also expressed Rho mutants containing a 48PRGDMP sequence with different C-terminal tails to examine the C-terminal effect on inhibiting platelet aggregation (Table B in S1 File). The IC₅₀ values of 48PRGDMP-65PR, 48PRGDMP-65PRYH, 48PRGDMP-65PRNGLYG, and 48PRGDMP-65PRNPWNG proteins were 155.2, 83.2, 96.9, and 130.9 nM, respectively. These results also showed that the length and amino acid contents of the C-terminus in Rho with a 48PRGDMP loop sequence may play a critical role in interacting with platelets integrin αIIbβ3.

### Table 3. Inhibition of integrins αIIbβ3, αvβ3, and α5β1 by Rho and its 48PRGDMP mutants.

| Proteins | αIIbβ3 | αvβ3 | α5β1 |
|----------|--------|------|------|
| RGD Loop | C-terminus | IC₅₀ (nM) | Q | IC₅₀ (nM) | Q | IC₅₀ (nM) | Q |
| 48PRGDMP | 65PRYH | 52.2±8.2 | 1.0 | 13.0±5.7 | 1.0 | 256.8±75.5 | 1.0 |
| 48PRGDMP | 65PR | 592.5±45.7 | 11.4 | 23.0±9.9 | 1.8 | 580.2±241.0 | 2.3 |
| 48PRGDMP | 65PRNGLYG | 186.0±11.1 | 3.6 | 26.7±3.3 | 2.1 | 238.1±19.7 | 0.9 |
| 48PRGDMP | 65PRNPWNG | 235.2±24.1 | 4.5 | 40.7±10.1 | 3.1 | 260.0±17.3 | 1.0 |
| Folds | | 1.0–11.4 | 1.0–1.8 | 0.9–2.3 |

Q ratio = IC₅₀ [Rho 48PRGDMP, 65PR mutant] / IC₅₀ [Rho]

https://doi.org/10.1371/journal.pone.0175321.t003

### Table 4. Inhibition of platelet aggregation and the binding of fibrinogen to platelets by Rho ARGDWN mutants.

| Proteins | Platelet aggregation | Fibrinogen-platelet binding |
|----------|----------------------|-----------------------------|
| RGD Loop | C-terminus | IC₅₀ (nM) | Q | IC₅₀ (nM) | Q |
| 48PRGDMP | 65PRYH | 83.2±10.4 | 1.0 | 90.8±28.9 |
| 48ARGDWN | 65PRNPWNG | 107.9±16.1 | 1.0 | 141.9±33.9 | 1.0 |
| 48ARGDWN | 65P | 235.1±30.5 | 2.2 | 450.8±112.9 | 3.2 |
| 48ARGDWN | 65PR | 171.4±4.2 | 1.6 | ND | ND |
| 48ARGDWN | 65PRY | 155.1±6.7 | 1.4 | ND | ND |
| 48ARGDWN | 65PRYH | 128.0±14.2 | 1.2 | 187.8±67.8 | 1.3 |
| 48ARGDWN | 65PRNGLYG | 105.2±13.3 | 1.0 | 123.1±22.7 | 0.9 |
| Folds | | 1.0–2.2 | 0.9–3.2 |

*Q ratio = IC₅₀ [Rho 48ARGDWN mutants] / IC₅₀ [Rho 48ARGDWN-65PRNPWNG mutant]*

ND, not determined.

https://doi.org/10.1371/journal.pone.0175321.t004
Inhibition of the binding of fibrinogen to platelets

The activity of ARGDWN mutants to inhibit the interaction between soluble fibrinogen and washed human platelets was evaluated. The analysis showed that the IC₅₀ values of 48ARGDWN, 65P, 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG proteins were 450.8, 187.8, 123.1, and 141.9 nM, respectively. In particular, 48ARGDWN-65P mutant exhibited 3.2-fold decrease in inhibiting the association between washed platelet and soluble fibrinogen in comparison with that of 48ARGDWN-65PRNPWNG mutant. These results were consistent with the results of platelet aggregation that the length of the C-terminus and the R66 residue of 48ARGDWN mutants are essential for interacting with platelets integrin αIIbβ3. In contrast to the result of the adhesion of cell-expressing integrin αIIbβ3 to immobilized fibrinogen, 48ARGDWN-65P mutant exhibited significant effect with 23.1-fold decrease in activity.

Structure determination

The solution structures of Rho 48ARGDWN-65PRYH, 65PRNGLYG, and 65PRNPWNG mutants expressed in P. pastoris were determined using NMR spectroscopy and the hybrid distance geometry-dynamical simulated annealing method. NOE-derived distance restraints were obtained from 2D NOESY and TOCSY and 3D 15N-edited TOCSY and 15N-edited NOESY. NMR spectra were recorded at pH 6. NMR assignments of Rho 48ARGDWN-65PRYH, 65PRNGLYG, and 65PRNPWNG mutants were obtained by analyzing standard 2D homonuclear and 3D heteronuclear NMR data (data not shown). The superimposition of the 1H,15N HSQC spectra of Rho 48ARGDWN-65PRYH, 65PRNGLYG, and 65PRNPWNG mutants showed that they exhibited the same secondary structures and tertiary fold (Fig 2). The secondary structures were identified based on networks of sequential and medium-range NOEs and 3JHNα coupling constants (Figure B in S1 File). Their six cysteine pairs (C4–C19, C6–C14, C13–C36, C27–C33, C32–C57, and C45–C64) and three short regions of two-stranded anti-parallel β-sheets (residues 13–14 and 20–21, 33–34 and 37–38, and 43–45 and 55–57) were also identified (data not shown).

According to the NOE spectra, the conformational differences were found in the C-terminal regions and their interactions with the ARGDWN loop (Figure C in S1 File). The NPWN residues of the 65PRNPWNG mutant formed a β-turn structure, which was reflected by the NOEs between Hα of N67 and HN of N70 and between Hα of P68 and HN of N70. In contrast, no turn structure was identified from the C-terminal regions of 48ARGDWN-65PRYH and 48ARGDWN-65PRNGLYG mutants.

The NOEs were found between the ARGDWN loop and their C-terminal regions, indicating that they were close to each other. For example, the NOEs between Hδ of W52 and Hε of H68, between and Hα of W52 and Hα of H68, and between Hε of W52 and Hε of H68 were found in the Rho 48ARGDWN-65PRYH mutant. The NOEs between Hα of W52 and Hδ of H68, between Hα of W52 and Hδ of H68, and between Hα of W52 and Hδ of H68 were found in the Rho 48ARGDWN-65PRNGLYG mutant. The NOEs between Hα of W52 and Hδ of H68, between Hα of W52 and Hδ of H68, and between Hα of W52 and Hδ of H68 were found in the Rho 48ARGDWN-65PRNPWNG mutant.

The 3D structures of the Rho 48ARGDWN-65PRYH, 65PRNGLYG, and 65PRNPWNG mutants were calculated using 1084, 1121, and 1142 experimentally derived restraints with an average of 15.9, 15.8, and 16.1 restraints per residue, respectively (Table 5). The backbone RMSD values of the Rho 48ARGDWN-65PRYH, 65PRNGLYG, and 65PRNPWNG mutants were
0.92 ± 0.16 Å, 1.05 ± 0.21 Å, and 1.09 ± 0.31 Å. The backbone RMSD values of the Rho 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants for the three β-sheet regions (13–14, 20–21, 33–34, 37–38, 43–45, and 55–57) were 0.41 ± 0.11 Å, 0.48 ± 0.14 Å, and 0.45 ± 0.13 Å, respectively. Based on the Ramachandran plot analysis, all of the dihedral angles were in the acceptable region. A summary of the restraints and structural statistics is shown in Table 5. The 20 most favorable structures of mutants from 200 initial structures are shown in Fig 3.

### Structural differences among rhodostomin 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants

Superimposing 3D structures of these mutants demonstrated that their overall structures were similar, except for the C-terminal regions and their interactions with the 48ARGDWN loop (Fig 4). The structural analysis also indicated that their 48ARGDWN loop exhibited similar conformations (Fig 4B). The C-terminal regions of these mutants exhibited distinct
Table 5. Summary of structural restraints and statistics for Rho 48ARGDWN mutants.

| Distance and dihedral angle restraints | 48ARGDWN-C-terminal mutants |
|----------------------------------------|-----------------------------|
|                                        | -65PRYH | -65PRNGLYG | -65PRNPWNG |
| Intra-residue                           | 152     | 160         | 165         |
| Sequential                              | 114     | 125         | 118         |
| Medium range                            | 365     | 369         | 392         |
| Long range                              | 383     | 392         | 393         |
| Hydrogen bond                           | 9       | 9           | 9           |
| Dihedral angles                         | 55      | 60          | 59          |
| Disulfide                               | 6       | 6           | 6           |
| Total                                   | 1084    | 1121        | 1142        |

Energy statistics X-plor energy (kcal mol⁻¹)

|                                        | Enoe    | Evdw    |
|----------------------------------------|---------|---------|
|                                        | 14.96±2.87 | 20.51±5.72 | 21.30±2.96 |

Geometric statistics

| Deviations from idealized geometry     | 48ARGDWN-C-terminal mutants |
|----------------------------------------|-----------------------------|
|                                        | -65PRYH | -65PRNGLYG | -65PRNPWNG |
| All backbone atoms (Å)                 | 0.92±0.16 | 1.05±0.21 | 1.09±0.31 |
| Backbone atoms (13–14, 20–21, 33–34, 37–38, 43–45, 55–57) (Å) | 0.41±0.11 | 0.48±0.14 | 0.45±0.13 |
| All heavy atoms (Å)                    | 1.42±0.14 | 1.50±0.18 | 1.53±0.31 |
| Heavy atoms (13–14, 20–21, 33–34, 37–38, 43–45, 55–57) (Å) | 0.86±0.11 | 0.93±0.16 | 0.95±0.14 |

Ramachandran analysis

| Most favored region (%) | 75.8 | 75.2 | 75.2 |
|-------------------------|------|------|------|
| Additionally allowed regions (%) | 21.2 | 20.7 | 20.4 |
| Generously allowed regions (%) | 2.9 | 4.1 | 4.4 |
| Disallowed regions (%) | 0.0 | 0.0 | 0.0 |

https://doi.org/10.1371/journal.pone.0175321.t005

Fig 3. 3D structures of Rho 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants. 

Ribbon representation of 20 lowest-energy NMR structures of Rho 48ARGDWN-65PRYH (A), 48ARGDWN-65PRNGLYG (B), and 48ARGDWN-65PRNPWNG (C). Cartoon representation of the averaged structure of Rho 48ARGDWN-65PRYH (D), 48ARGDWN-65PRNGLYG (E) and 48ARGDWN-65PRNPWNG (F) mutant. The β-strands are shown in cyan. The structures are superposed on the main-chain atoms of the β-strands.

https://doi.org/10.1371/journal.pone.0175321.g003
conformations: the YH residues of the $^{48}$ARGDWN-$^{65}$PRYH mutant had an extended structure; the NGLYG residues of the $^{48}$ARGDWN-$^{65}$PRNGLYG mutant had a turn-like structure; and the NPWN residues of the $^{48}$ARGDWN-$^{65}$PRNPWNG mutant formed a $\beta$-turn structure (Fig 4C). The interactions between the ARGDWN loop and C-terminal regions were extremely different. Our analysis demonstrated that the W52 sidechain of the $^{48}$ARGDWN-$^{65}$PRYH, $^{48}$ARGDWN-$^{65}$PRNGLYG, and $^{48}$ARGDWN-$^{65}$PRNPWNG mutants mainly interacted with H68 of $^{65}$PRYH (Fig 4D), with L69 of $^{65}$PRNGLYG (Fig 4E), and with N70 of $^{65}$PRNPWNG (Fig 4F), respectively. In addition, the A48 sidechain of the $^{48}$ARGDWN-$^{65}$PRNPWNG mutant interacted with the N70 residue of the C-terminal region, and this interaction was not found in two other mutants. These structural differences may be correlated with their functional differences.

Interaction differences in the docking models of integrin $\alpha$IIb$\beta$3-rhodostomin $^{48}$ARGDWN-$^{65}$P, $^{48}$ARGDWN-$^{65}$PRNGLYG, and $^{48}$ARGDWN-$^{65}$PRNPWNG mutant complexes

The docking of $^{48}$ARGDWN-$^{65}$P, $^{48}$ARGDWN-$^{65}$PRNGLYG, and $^{48}$ARGDWN-$^{65}$PRNPWNG mutants into integrin $\alpha$IIb$\beta$3 was used to simulate their interactions with integrin $\alpha$IIb$\beta$3. The
models of these integrin αIIbβ3 complexes were built using the HADDOCK webserver [33]. The distance and hydrogen bond restraints were derived from the X-ray structure of integrin αIIbβ3 complexed with a GRGDSP hexapeptide (PDB code 3ZE2), including eight key interactions between integrin and the R and D residues (Table C in S1 File). Specifically, the R residue formed a salt bridge with the D224, hydrogen bonds with the Y189 and S225 residues, and a cation-π interaction with the F231 of the αIIb subunit. The carboxylate oxygen of the D residue contacted a Mn^{2+} ion and formed hydrogen bonds with the S123 residues of the β3 subunit. The other carboxyl oxygen of the D residue formed hydrogen bonds with the Y122 and N215 residues of the β3 subunit, and the backbone amide of the D residue formed a hydrogen bond with the R216 residue of subunit β3.

Using these restraints, we docked Rho ARGDWN mutants to integrin αIIbβ3. The structure cluster was selected based on the lowest Z-score without restraint violations. The Z-score values of the 48ARGDWN-65P, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants were -1, -1.2, and -1, and their electrostatic energies were -515.9, -569.5, and -630.7 kcal/mol, respectively (Table D in S1 File). This was consistent with the effects of cell adhesion data on integrin αIIbβ3 that 48ARGDWN-65P and 48ARGDWN-65PRNPWNG mutants exhibited the lowest and highest inhibitory activities. The resulting structures showed that Rho mutants fitted into a crevice between the propeller domain of the αIIb subunit and the βA domain of the β3 subunit on the αIIbβ3 headpiece. The analysis showed that the docking of these mutants into integrin αIIbβ3 resulted in the same numbers of contacts for the 48ARGDWN loop (Table 6). The key contacts included seven hydrogen bonds and two salt bridges between the R and D residues of the RGD motif and integrin. In particular, the contacts of the hydrogen bond and salt bridge between the R49 residue of Rho mutants and the Y189 and D224 residues of the αIIb subunit, and the hydrogen bond between the D51 residue of Rho mutants and the Y122, S123, N215, and R216 residues of the β3 subunit were exhibited by all the mutants (Fig 5A). The major differences between the mutants were the interactions between integrin αIIbβ3 and the C-terminal regions of the Rho mutants (Table 6). The C-terminal region of the 48ARGDWN-65P deletion mutant did not exhibit any interaction with integrin αIIbβ3 (Table 6). In contrast, the C-terminal regions of the 48ARGDWN-65PRNGLYG and 48ARGDWN-65PRNPWNG mutants extensively interacted with integrin αIIbβ3 (Table 6). For example, the C-terminal region of the G71 residue of the 48ARGDWN-65PRNGLYG mutant formed a hydrogen bond with the V156 residue of the αIIb subunit (Fig 5B and Table 6). The W69 and N70 residues of 48ARGDWN-65PRNPWNG exhibited cation-π interaction with the K125 residue of the β3 subunit and a hydrogen bond with the D159 residue of the αIIb subunit (Fig 5C and Table 6). In contrast to 48ARGDWN-65P mutant, the R66 residue of 48ARGDWN-65PRNGLYG and 48ARGDWN-65PRNPWNG mutants interacted with the D159 residue of the αIIb subunit. These results suggested that the contents of the C-terminal regions in disintegrins are critical to their abilities to bind to integrin αIIbβ3.

**Discussion**

Many studies have shown that alternations in the RGD loop and C-terminal region of disintegrins affect their binding specificities and affinities [8–19]. In this study, we find that the sequence contents of the RGD loop and C-terminus of disintegrins mutually affected their conformations, resulting in functional and structural differences in integrin binding. We demonstrated that Rho mutants containing a 48ARGDWN-65PRNPWNG sequence exhibited the highest selectivity in inhibiting integrin αIIbβ3-mediated cell adhesion. Cell adhesion analysis also indicated that the C-terminal region of Rho was highly sensitive to integrin αIIbβ3. Based on the results of cell adhesion, platelet aggregation and the binding of fibrinogen to platelet
inhibited by ARGDWN mutants, integrin αIIbβ3 of platelets bound differently to immobilized and soluble fibrinogen. The results of platelet aggregation and integrin αIIbβ3-mediated cell adhesion showed that the R66 and Y67 residues may play important roles in inhibiting the binding of platelet to soluble fibrinogen and the adhesion of integrin αIIbβ3 to immobilized fibrinogen, respectively. NMR structural analysis of 48ARGDWN-65PRYH, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants showed that their C-terminal regions

Table 6. Summary of the interactions between Rho 48ARGDWN-65P, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants and integrin αIIbβ3.

| Rho Mutant | Integrin | Rho Mutant | Integrin | Rho Mutant | Integrin |
|------------|----------|------------|----------|------------|----------|
| 65P        | αIIb     | β3         | 65PRNGLYG| αIIb       | β3       |
| A48        | F160     | A48        | A218     | A48        | F231     |
| R49        | F160     | R49        | Y189<sup>HB</sup> | A218<sup>HB</sup> | R49        | Y189<sup>HB</sup> |
|            | Y189<sup>SB</sup> | Y190 | L192<sup>SB</sup> | D224<sup>SB</sup> | S225 | F231<sup>CP</sup> |
|            | Y190 | L192 | D224<sup>SB</sup> | S225 | F231<sup>CP</sup> |
|            | D224<sup>SB</sup> | S225 | F231<sup>CP</sup> |
|            | S225 | F231<sup>CP</sup> |
| G50        | R216     | G50        | R216     | G50        | Y190     |
|            | A218     | D217       | A218     |             | A218     |
| D51        | S121     | D51        | S121     | D51        | S121     |
|            | Y122<sup>HB</sup> | S123<sup>HB</sup> | R214 | N215<sup>HB</sup> | R216<sup>HB</sup> | D217<sup>HB</sup> | A218 | E220 | Mn<sup>2+</sup> | |
|            | Y122<sup>HB</sup> | S123<sup>HB</sup> | R214 | N215<sup>HB</sup> | R216<sup>HB</sup> | D217<sup>HB</sup> | A218 | E220 | Mn<sup>2+</sup> | |
| W52        | F160     | W52        | F160     | W52        | F160     |
|            | Y122     | Y190       | S123     | S123       | Y190     |
|            | S123     | S123       |
| N53        | Y122     | N53        | D126<sup>HB</sup> | N53        | S123<sup>HB</sup> | D126<sup>HB</sup> | D251 |
|            | S123<sup>HB</sup> | D126<sup>HB</sup> | D251 |
|            | K125     | D126<sup>HB</sup> | D251 |
| R66        | D159     | R66        | D159     |             |             |
| L69        | Y122     | W69        | V156     | Y122       |             |
|            | M180     | V156       | Y122     |             |
| Y70        | V156     | N70        | D159<sup>HB</sup> |             |
|            | D159     |             |             |
| G71        | V156<sup>HB</sup> | G71        | D159     |             |
|            | E157     |             |             |

<sup>HB</sup>, hydrogen bond; <sup>SB</sup>, salt bridge; <sup>CP</sup>, cation-π

https://doi.org/10.1371/journal.pone.0175321.t006
exhibited distinct conformations. Molecular docking results suggest that the sequence contents and the length of the C-terminal regions in disintegrins are critical to their ability to bind to integrin αIIbβ3. We provide the first structural evidence that the diverse RGD loop and C-terminus of medium disintegrins interact to regulate their conformations, resulting in functional differences in integrin binding.

The structural analysis of wild-type Rho and its 48ARGDWN mutants also showed that a conformational difference existed in the 3D conformation of the RGD loop (Fig 6A). Many studies have demonstrated that a key feature of integrin αIIbβ3 antagonists is the presence of an anionic carboxy-terminal (CO$_2^-$) separated by a spatial chemical moiety and a certain distance from the cationic basic amino-terminal of benzamidine, piperidine, and guanidine [36]. The distance between the anionic (D) and cationic (R) terminals is crucial to the

---

Fig 5. The docking of 48ARGDWN-65P, 48ARGDWN-65PRNGLYG, and 48ARGDWN-65PRNPWNG mutants into integrin αIIbβ3. The contact surface between the ARGDWN loop and integrin αIIbβ3 is shown in (A). The propeller domain of cIIb subunit and the A domain of β3 subunit are shown in purple and pink, respectively. The interacting residues are shown in the ball-and-stick representation, and hydrogen bonds are displayed by broken lines. The C-terminal 65PRNGLYG region of 48ARGDWN (B) and the C-terminal 65PRNPWNG region of 48ARGDWN (C) mutants are shown.

https://doi.org/10.1371/journal.pone.0175321.g005

Fig 6. Structural comparison of rho and its 48ARGDWN-65PRYH mutant. Ribbon representation of the ten-residue RGD loop (residues 46 to 54) (A) and all backbone (B) of the averaged structures of rho and its 48ARGDWN-65PRYH mutant are superimposed and shown in grey and red, respectively. The RMS deviation of the secondary structure backbone atom was 0.692 Å. The distances between Co-to-Co of the residues 52 and 68 of Rho and its 48ARGDWN-65PRYH mutant are 12.2 and 8.0 Å, respectively.

https://doi.org/10.1371/journal.pone.0175321.g006
optimal binding affinity and specificity for various integrins. Specifically, the distances between the R and D residues of RGD-containing peptides can be optimally designed for the selective recognition of integrins αIIbβ3, αvβ3, and α5β1 [37]. Therefore, we analyzed the distances between Cα-to-Cα, Cβ-to-Cβ, and Cζ-to-Cγ of the R(i) and D(i+2) residues, and between Cα-to-Cα of the R(i) and X(i+3) residues of Rho, its mutants, and RGD-containing peptides (Table 7). We found that the distance between the Cα-to-Cα of the R(i) and X(i+3) residues was correlated with their integrin specificity. The Cα-to-Cα distances of the R(i) and X(i+3) residues in eptifibatide, an integrin antagonist, were 7.6 and 5.4 Å, respectively. The average Cα-to-Cα distances of the R(i) and W/M(i+3) residues in Rho 48ARGDWN mutants and Rho with a 48PRGDMP sequence were 7.3 to 7.6 Å and 6.5 Å, respectively. These results indicated that the Cα-to-Cα distances of the R(i) and X(i+3) residues of the integrin αIIbβ3-specific antagonist were larger than that of the integrin αvβ3 antagonist. This demonstrated that the W52 residue increased the Cα-to-Cα distance between R(i) and W(i+3) of the 48ARGDWN motif, resulting in its selectivity to integrin αIIbβ3. Our results were consistent with the previous hypothesis that integrin αIIbβ3-specific disintegrin prefers a larger Cα(i)-to-Cα(i+3) distance in its RGDX motif [8].

Many studies have shown that the C-terminal tails of disintegrins are located in the proximity of the RGD loop, the integrin-binding loop, and that the C-terminal regions of disintegrins play synergistic roles in interacting with RGD-binding integrins [16, 18, 20, 21, 25]. For example, C-terminal W67 of flavoridin with an 48ARGDFP motif is close to D55 [21], C-terminal Y67 of Rho with a 48PRGDMP motif is close to D55 [25], and C-terminal W67 of trimestatin with a 48ARGDNP motif is close to P53 [18]. The structural analysis of wild-type Rho and its 48ARGDWN mutants also showed that a conformational difference existed in their RGD loop and C-terminal region (Fig 6B). In contrast to that of Rho, structural analyses of the Rho 48ARGDWN-65PRYH mutant indicated that C-terminal H68 is close to W52. C-terminal L69 of the 48ARGDWN-65PRNGLYG mutant is close to W52, and the C-terminal N70 residue of the 48ARGDWN-65PRNGWNG mutant is close to W52 and A48. We also found that the NPWN region of the 48ARGDWN-65PRNPWNG mutant formed a type I β-turn, which was not found in other C-terminal mutants. These results suggest that the sequence contents of the C-terminal region and RGD loop of disintegrins are important for their 3D conformation and mutual interactions. These structural differences may be correlated with their functional differences.

### Table 7. Comparison of the Cα(Ri)-Cα(Di+2), Cβ(Ri)-Cβ(Di+2), Cc(Ri)-Cc(Di+2), and Cα(Ri)-Cc(Xi+3) distances (Å) of integrin ligands.

| Ligands       | RGD motif       | Cα(Ri)-Cα(Di+2) | Cβ(Ri)-Cβ(Di+2) | Cc(Ri)-Cc(Di+2) | Cα(Ri)-Cc(Xi+3) |
|---------------|-----------------|----------------|----------------|----------------|----------------|
| Eptifibatidea | HrgGDWP         | 6.9 ± 0.4       | 8.6 ± 0.6       | 12.7 ± 1.1     | 7.3 ± 0.5      |
| RGD peptideb | GRGDSP          | 7.1 ± 0.3       | 8.8 ± 0.2       | 12.4 ± 1.1     | 7.6 ± 0.4      |
| Cilengitidéc | c(-RGD[NMe]V-)  | 6.4 ± 0.5       | 8.1 ± 0.0       | 11.9 ± 1.4     | 6.5 ± 0.6      |
| 48ARGDWN,65PRYH | ARGDWN       | 6.5 ± 0.3       | 8.9 ± 0.3       | 13.0 ± 1.1     | 7.6 ± 0.3      |
| 48ARGDWN,65PRNGLYG | ARGDWN    | 6.5 ± 0.3       | 8.8 ± 0.4       | 12.4 ± 1.1     | 7.6 ± 0.4      |
| 48ARGDWN,65PRNPWNG | ARGDWN    | 6.5 ± 0.3       | 8.1 ± 1.0       | 11.9 ± 1.4     | 6.5 ± 0.6      |
| Rhodostominf | PRGDMP         | 6.3 ± 0.5       | 8.1 ± 1.0       | 11.9 ± 1.4     | 6.5 ± 0.6      |

a The antagonist of integrin αIIbβ3; PDB code: 2VDN
b The antagonist of integrin αIIbβ3; PDB code: 3ZE2
c The antagonist of integrins αvβ3 and αvβ5; PDB code: 1L5G
f PDB code: 2PJF

doi:10.1371/journal.pone.0175321.t007

The roles of RGD loop and C-terminus of medium disintegrins

https://doi.org/10.1371/journal.pone.0175321.t007
Integrins are known for their ability to bind multiple ligands due to flexibility in their binding sites. Many studies showed that integrin αIβ3 adhesion on fibrinogen is mediated by recognition sequences RGDF (Aα95–98), RGDS (Aα572–575), and HHLGGAKQAGDV (γ 400–411) of fibrinogen [38–41]. In particular, different recognition sites of soluble and immobilized fibrinogen are used for their binding to integrin αIβ3 [38, 39]. For example, integrin αIβ3 binds to soluble fibrinogen mainly through HHLGGAKQAGDV (γ 400–411). Integrin αIβ3 binds to immobilized fibrinogen through not only HHLGGAKQAGDV (γ 400–411) but also RGDF (Aα95–98). In contrast to integrin α/β3 adhesion on fibrinogen, it is only mediated by the carboxyl-terminal RGDS site of the Aα chain [4141]. Our findings revealed that Rho 48 ARGDWN mutants selectively inhibited integrin αIβ3 to immobilized and soluble fibrinogen, and the incorporation of C-terminal NPWNG increased its inhibitory activity to immobilized fibrinogen. However, it is likely that the specificity of Rho ARGDWN mutants with C-terminal PRNPWNG sequence towards αIβ3 antagonism could be due to better competition with not only RGD but also the γ-chain ligands as well. Although functional and structural differences in ARGDWN mutants and their integrin αIβ3 complexes were found from our study, it is uncertain that these interactions may take place in vivo and are affected by the ionic milieu. The effect of recognition by the inside-out signaling on integrin cannot be also excluded as well.

In conclusion, our functional and structural analyses demonstrated that the RGD loop and C-terminus of rhodostomin mutants interact with each other. The amino acid sequences of the RGD loop and C-terminal regions in medium disintegrins are important for their interactions and abilities to the binding of integrin αIβ3 to immobilized and soluble fibrinogen. These findings provide new insights into the structure-based drug design of integrin αIβ3 antagonist by using the disintegrin scaffold, and they serve as a basis for exploring the structure-function relationships of RGD-binding integrins and their ligands.

Supporting information

S1 File.

Figure A. Mass spectra of recombinant Rho and its mutants. (A) mass spectrum of 48PRGDMP-65PR mutant, (B) mass spectrum of 48PRGDMP-65PRYH (Rho), (C) mass spectrum of 48PRGDMP-65PRNGLYG mutant, (D) mass spectrum of 48PRGDMP-65PRNPWNG mutant, (E) mass spectrum of 48ARGDWN-65P mutant, (F) mass spectrum of 48ARGDWN-65PR mutant, (G) mass spectrum of 48ARGDWN-65PRY mutant, (H) mass spectrum of 48ARGDWN-65PRYH mutant, (I) mass spectrum of 48ARGDWN-65PRNPWNG and (J) mass spectrum of 48ARGDWN-65PRNPWNG mutant.

Figure B. Summary of NMR data for 48ARGDWN, 65PRYH (A), 48ARGDWN, 65PRNPWNG (B), and 48ARGDWN, 65PRNPWNG (C) mutants. The intensities of NOEs are represented by the thickness of the blocks.

Figure C. Amide strip plots and 2D 1H–1H NOESY spectra of Rho 48ARGDWN mutants. (A) Amide strip plots of W52 and N67 to G71 of 48ARGDWN, 65PRNPWNG at pH 6.0. The dNN (i, i +1) and dNZ (i, i +1) NOE connectivities are shown. 2D 1H–1H NOESY spectra of 48ARGDWN, 67YH (B) in 100% D2O, 48ARGDWN, 67NGLYG (C) in 100% D2O and 48ARGDWN, 67NPWNG (D, E) in H2O: D2O (9:1, v/v) show NOE connections between RGD loop and C-terminal region. (D) NOE connections between sidechain NH of W52 and the protons of the RGD loop and C-terminal region. (E) NOE connections between the protons of the RGD loop and C-terminal region. The NOEs between the ARGDWN loop and their C-terminal regions were shown in red.

Table A. Molecular weights of recombinant Rho and its mutants.
Table B. Inhibition of platelet aggregation by Rho and its C-terminal mutants.
Table C. Summary of the interactions between the GRGDSP peptide and integrin αIIbβ3 (PDB code: 3ZE2).
Table D. Statistical analysis of integrin αIIbβ3–Rho mutants docking results obtained by Haddock webservice.

Acknowledgments
NMR spectra were obtained at National Cheng Kung University or from the High-Field Biomacromolecular NMR Core Facility supported by the National Research Program for Genomic Medicine. We are grateful to Drs. Wen-Mei Fu, Wenya Huang, and Tur-Fu Huang for helpful discussions. This work was supported by the research grants from the Ministry of Science and Technology (MOST-105-2325-B-006-004), Taiwan, Republic of China.

Author Contributions
Conceptualization: WJC YTC.
Data curation: YTC JHS.
Formal analysis: YTC JHS CYC.
Funding acquisition: WJC.
Investigation: YTC WJC.
Methodology: YTC CHH YCC CYC YSC WJC.
Project administration: YTC WJC.
Resources: YTC JHS CHH YCC CYC YSC WJC.
Software: YTC JHS WJC.
Supervision: YTC WJC.
Validation: YTC CYC WJC.
Visualization: YTC WJC.
Writing – original draft: YTC WJC.
Writing – review & editing: YTC WJC.

References
1. Blobel CP, White JM. Structure, function and evolutionary relationship of proteins containing a disintegrin domain. Current opinion in cell biology. 1992; 4(5):760–5. Epub 1992/10/01. PMID: 1419054
2. McLane MA, Sanchez EE, Wong A, Paquette-Straub C, Perez JC. Disintegrins. Current drug targets Cardiovascular & haematological disorders. 2004; 4(4):327–55. Epub 2004/12/08.
3. Gould RJ, Polokoff MA, Friedman PA, Huang TF, Holt JC, Cook JJ, et al. Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine (New York, NY). 1990; 195(2):168–71. Epub 1990/11/01.
4. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. The Journal of biological chemistry. 1987; 262(33):16157–63. Epub 1987/11/25. PMID: 3680247
5. Calvete JJ, Marcinkiewicz C, Monleon D, Esteve V, Celda B, Juarez P, et al. Snake venom disintegrins: evolution of structure and function. Toxicon: official journal of the International Society on Toxinology. 2005; 45(8):1063–74. Epub 2005/06/01.

6. Calvete JJ, Moreno-Murciano MP, Theakston RD, Kisiel DG, Marcinkiewicz C. Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering. The Biochemical journal. 2003; 372(Pt 3):725–34. Epub 2003/04/02. https://doi.org/10.1042/BJ20021739 PMID: 12667142

7. Takagi J. Structural basis for ligand recognition by integrins. Current opinion in cell biology. 2007; 19(5):557–64. Epub 2007/10/19. https://doi.org/10.1016/j.ceb.2007.09.002 PMID: 17942298

8. McLane MA, Vijay-Kumar S, Marcinkiewicz C, Calvete JJ, Niewiarowski S. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS letters. 1996; 391(1–2):139–43. Epub 1996/08/05. PMID: 8706902

9. Dennis MS, Carter P, Lazarus RA. Binding interactions of kistrin with platelet glycoprotein IIb-IIIa: analysis by site-directed mutagenesis. Proteins. 1993; 15(3):312–21. Epub 1993/03/01. https://doi.org/10.1002/prot.340150308 PMID: 8456099

10. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. The Journal of biological chemistry. 1993; 268(2):1058–65. Epub 1993/01/15. PMID: 8419314

11. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of alpha IIb beta3 and alpha(v)beta3 integrins and expression of ligand-induced binding site. Blood. 1997; 90(4):1565–75. Epub 1997/08/15. PMID: 9299775

12. Shiu JH, Chen CY, Chang LS, Chen YC, Chen YC, Lo YH, et al. Solution structure of gamma-bungarotoxin: the functional significance of amino acid residues flanking the RGD motif in integrin binding. Proteins. 2004; 57(4):839–49. Epub 2004/09/25. https://doi.org/10.1002/prot.20269 PMID: 15390258

13. Rahman S, Atkenn A, Flynn G, Formstone C, Savidge GF. Modulation of RGD sequence motifs regulates disintegrin recognition of alphabeta3 and alphabeta1 integrin complexes. Replacement of elegantin alanine-50 with proline, N-terminal to the RGD sequence, diminishes recognition of the alphabeta1 complex with restoration induced by Mn2+ cation. The Biochemical journal. 1998; 335(2):247–57. Epub 1998/10/06.

14. Shiu JH, Chen CY, Chang YT, Chang YS, Huang CH, et al. Effect of P to A mutation of the N-terminal residue adjacent to the RGD motif on rhodostomin: importance of dynamics in integrin recognition. PloS one. 2012; 7(1):e28833. Epub 2012/01/13. https://doi.org/10.1371/journal.pone.0028833 PMID: 22238583

15. Chen YC, Cheng CH, Shiu JH, Chang YT, Chang YS, Huang CH, et al. Expression in Pichia pastoris and characterization of echistatin, an RGD-containing short disintegrin. Toxicon: official journal of the International Society on Toxinology. 2012; 60(8):1342–8. Epub 2012/09/18.

16. Monleon D, Esteve V, Kovacs H, Calvete JJ, Celda B. Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR. The Biochemical journal. 2005; 387(1):57–66. Epub 2004/11/13. https://doi.org/10.1042/BJ20041343 PMID: 15535803

17. Wierzbicka-Patynowski I, Niewiarowski S, Marcinkiewicz C, Calvete JJ, Marcinkiewicz MM, McLane MA. Structural requirements of echistatin for the recognition of alphabeta3 and alphabeta1 integrins. The Journal of biological chemistry. 1999; 274(53):37809–14. Epub 1999/12/23. PMID: 10608843

18. Fujii Y, Okuda F, Fujimoto Z, Horii K, Morita T, Mizuno H. Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD. Journal of molecular biology. 2003; 332(5):1115–22. Epub 2003/09/23. PMID: 14496613

19. McLane MA, Kuchar MA, Brando C, Santoli D, Paquette-Straub CA, Miele ME. New insights on disintegrin-receptor interactions: eristostatin and melanoma cells. Haemostasis. 2001; 31(3–6):177–82. Epub 2002/03/23. PMID: 11910183

20. McLane MA, Zhang X, Tian J, Zelinskas C, Srivastava A, Hensley B, et al. Scratching below the surface: wound healing and alanine mutagenesis provide unique insights into interactions between eristostatin, platelets and melanoma cells. Pathophysiology of haemostasis and thrombosis. 2005; 34(4–5):164–8. Epub 2006/05/19. https://doi.org/10.1159/000092417 PMID: 16707921

21. Senn H, Klaus W. The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet GP IIb-IIIa receptor. Journal of molecular biology. 1993; 232(3):907–25. Epub 1993/08/05. https://doi.org/10.1006/jmbi.1993.1439 PMID: 8355277
22. Yahalom D, Wittelsberger A, Mierke DF, Rosenblatt M, Alexander JM, Chorev M. Identification of the principal binding site for RGD-containing ligands in the alpha(V)beta(3) integrin: a photoaffinity cross-linking study. Biochemistry. 2002; 41(26):8321–31. Epub 2002/06/26. PMID: 12081480

23. McLane MA, Kowalska MA, Silver L, Shattil SJ, Niewiarowski S. Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets. The Biochemical journal. 1994; 301(Pt 2):429–36. Epub 1994/07/15.

24. Huang TF, Sheu JR, Teng CM, Chen SW, Liu CS. Triflavin, an antiplatelet Arg-Gly-Asp-containing peptide, is a specific antagonist of platelet membrane glycoprotein IIb-IIIa complex. Journal of biochemistry. 1991; 109(2):328–34. Epub 1991/02/01. PMID: 1864844

25. Guo RT, Chou LJ, Chen YC, Chen CY, Pari K, Jen CJ, et al. Expression in Pichia pastoris and characterization by circular dichroism and NMR of rhodostomin. Proteins. 2001; 43(4):499–508. PMID: 11340665

26. Chen CY, Cheng CH, Chen YC, Lee JC, Chou SH, Huang W, et al. Preparation of amino-acid-type selective isotope labeling of protein expressed in Pichia pastoris. Proteins. 2006; 62(1):279–87. Epub 2005/11/12. https://doi.org/10.1002/prot.20742 PMID: 16283643

27. Chen CY, Shiu JH, Hsieh YH, Liu YC, Chen YC, Chen YC, et al. Effect of D to E mutation of the RGD motif in rhodostomin on its activity, structure, and dynamics: importance of the interactions between the D residue and integrin. Proteins. 2009; 76(4):808–21. Epub 2009/03/13. https://doi.org/10.1002/prot.22387 PMID: 19280603

28. Cheng CH, Chen YC, Shiu JH, Chang YT, Chang YS, Huang CH, et al. Dynamics and functional differences between dendroaspin and rhodostomin: insights into protein scaffolds in integrin recognition. Protein science: a publication of the Protein Society. 2012; 21(12):1872–84. Epub 2012/10/04.

29. Shanley DK, Kiely PA, Golla K, Allen S, Martin K, O'Riordan RT, et al. Pregnancy-specific glycoproteins bind integrin alphabeta3 and inhibit the platelet-fibrinogen interaction. PloS one. 2013; 8(2):e57491. Epub 2013/02/08. https://doi.org/10.1371/journal.pone.0057491 PMID: 23469002

30. Brunger AT. X-PLOR: version 3.1: a system for x-ray crystallography and NMR. New Haven: Yale University Press; 1992.

31. Nilges M, Clore GM, Gronenborn AM. Determination of three-dimensional structures of proteins from interproton distance data by dynamical simulated annealing from a random array of atoms. Circumventing problems associated with folding. FEBS letters. 1988; 239(1):129–36. PMID: 3181419

32. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph. 1996; 14(1):51–5, 29–32. PMID: 8744573

33. de Vries SJ, van Dijk M, Bonvin AM. The HADDOCK web server for data-driven biomolecular docking. Nature protocols. 2010; 5(5):883–97. Epub 2010/05/01. https://doi.org/10.1038/nprot.2010.32 PMID: 20431534

34. Zhu J, Zhu J, Springer TA. Complete integrin headpiece opening in eight steps. The Journal of cell biology. 2013; 201(7):1053–68. Epub 2013/06/27. https://doi.org/10.1083/jcb.201212037 PMID: 23798730

35. Gallivan JP, Dougherty DA. Cation-pi interactions in structural biology. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(17):9459–64. Epub 1999/08/18. PMID: 10449714

36. Mousa SA. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug discovery today. 1999; 4(12):552–61. Epub 1999/11/11. PMID: 10557137

37. Mas-Moruno C, Rechennacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anti-cancer agents in medicinal chemistry. 2010; 10(10):753–68. Epub 2011/01/29. https://doi.org/10.2174/187152010794728639 PMID: 21269250

38. Farrell DH, Thigagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89(22):10729–32. Epub 1992/11/15. PMID: 1438269

39. Zamarron C, Ginsberg MH, Plow EF. A receptor-induced binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa. The Journal of biological chemistry. 1991; 266(24):16193–9. Epub 1991/08/25. PMID: 1714910

40. Savage B, Bottini E, Ruggeri ZM. Interaction of integrin alpha IIb beta 3 with multiple fibrinogen domains during platelet adhesion. The Journal of biological chemistry. 1995; 270(48):28812–7. Epub 1995/12/01. PMID: 7499405

41. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM. Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell. 1989; 58(5):945–53. Epub 1989/09/08. PMID: 2673537